Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.62 |
| ▸ | BCL2 | P10415 | 2/20 | 0.54 |
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | YAP1 | P46937 | 2/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3498722 | 1.00 | PTPN1 (0.62) | PTPN1BCL2CTSSCTSKYAP1 | |
| SCHEMBL16935712 | 0.92 | CTSS (0.58) | PTPN1CTSSCTSKITGB3ITGA2B | |
| SCHEMBL18920552 | 0.92 | CTSS (0.58) | PTPN1CTSSCTSKITGB3ITGA2B | |
| SCHEMBL2617261 | 0.92 | CTSS (0.58) | PTPN1CTSSCTSKITGB3ITGA2B | |
| SCHEMBL539374 | 0.89 | CTSS (0.62) | PTPN1BCL2CTSSCTSKITGB3 | |
| SCHEMBL539373 | 0.89 | CTSS (0.62) | PTPN1BCL2CTSSCTSKITGB3 | |
| SCHEMBL10634012 | 0.88 | PTPN1 (0.50) | PTPN1BCL2CTSSCTSKYAP1 | |
| SCHEMBL6161729 | 0.88 | BCL2 (0.64) | PTPN1BCL2CTSSCTSKYAP1 | |
| SCHEMBL3350988 | 0.88 | BCL2 (0.64) | PTPN1BCL2CTSSCTSKYAP1 | |
| SCHEMBL3500186 | 0.88 | BCL2 (0.64) | PTPN1BCL2CTSSCTSKYAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | KUREHA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | PTPN1 3494/4885BCL2 2066/4885CTSS 3589/4885 |
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | HDAC5, HDAC1, HDAC9 | PTPN1 3437/4885BCL2 3483/4885CTSS 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.